influenza
virus
caus
annual
epidem
irregular
pandem
vaccin
heterosubtyp
protect
heteroprotect
need
present
studi
variou
influenza
hemagglutinin
ha
protein
express
insect
cell
mice
subcutan
immun
express
ha
protein
challeng
influenza
virus
apuerto
result
first
show
wildtyp
hemagglutinin
ha
transmembran
domain
tm
mutant
heteroprotect
surviv
rate
respect
wildtyp
heteroprotect
except
surviv
rate
tm
replac
tm
gener
recombin
respect
whether
tmdepend
heteroprotect
could
transfer
tm
mutant
investig
result
show
tmdepend
heteroprotect
transfer
surviv
rate
respect
surviv
rate
respect
furthermor
higher
dosag
score
heteroprotect
result
demonstr
replac
tm
tm
could
enhanc
heteroprotect
find
would
help
develop
futur
influenza
vaccin
pandem
recent
appear
infect
influenza
virus
member
famili
orthomyxovirida
segment
genom
consist
eight
segment
encod
least
protein
classifi
subtyp
base
hemagglutinin
ha
neuraminidas
na
express
viral
surfac
recent
discoveri
subtyp
bat
expand
influenza
virus
ha
subtyp
ha
main
surfac
antigen
respons
viru
entri
fusion
activ
accumul
point
mutat
within
antibodybind
site
ha
call
antigen
drift
caus
annual
epidem
introduct
ha
human
reassort
viru
refer
antigen
shift
associ
irregular
pandem
recent
emerg
avian
influenza
china
vivid
remind
danger
influenza
pandem
still
immin
main
defens
influenza
epidem
pandem
vaccin
includ
season
trivalentquadrival
inactiv
viru
tivqiv
vaccin
live
attenu
viru
vaccin
inactiv
viru
vaccin
first
introduc
year
ago
current
qiv
vaccin
consist
strain
strain
b
yamagata
b
victoria
strain
becom
avail
howev
tivqiv
vaccin
need
least
two
imper
improv
one
overcom
depend
upon
chicken
egg
viral
propag
increas
crossprotect
immun
heteroprotect
tivqiv
vaccin
provid
littl
protect
http
elsevi
ltd
right
reserv
gross
antigen
mismatch
vaccin
strain
circul
strain
commerci
avail
trival
ha
subunit
th
vaccin
flublok
consist
three
insectcellderiv
full
length
season
tiv
vaccin
repres
success
overcom
chickenegg
depend
heteroprotect
tiv
th
vaccin
larg
overlook
univers
vaccin
develop
platform
exampl
hemagglutinin
stalk
domainbas
vaccin
npbase
dna
vaccin
subunit
vaccin
crossreact
monoclon
antibodi
studi
group
demonstr
plausibl
correl
ha
stabil
immun
exampl
ectodomain
ha
protein
fuse
foldon
domain
fibritin
bacteri
phage
trimer
repeat
ferritin
fusion
protein
show
increas
stabil
consequ
improv
potenc
breadth
crossreact
immun
previou
studi
show
wildtyp
higher
thermal
stabil
mutant
mutat
two
cystein
present
transmembran
domain
tm
sinc
two
tm
cystein
ha
uniqu
studi
extend
investig
whether
without
two
tm
cystein
less
heteroprotect
whether
replac
tm
tm
could
increas
heteroprotect
data
show
recombin
ha
protein
replac
tm
exhibit
enhanc
heteroprotect
spodoptera
frugiperda
cell
cell
maintain
serum
free
medium
gibco
influenza
apuerto
obtain
wuhan
institut
virolog
ca
influenza
south
china
agricultur
univers
two
virus
adapt
balbc
mice
viru
challeng
laboratori
mous
lethal
dose
determin
reassort
viru
deriv
ha
na
gene
viru
six
intern
gene
highgrowth
apuerto
viru
use
inactiv
viru
particl
obtain
harbin
veterinari
research
institut
harbin
china
isol
maintain
laboratori
live
virus
first
propag
embryon
chicken
egg
inactiv
purifi
use
immunolog
studi
sitespecif
mutagenesi
clone
recombin
baculoviru
gener
infect
perform
previous
describ
briefli
dna
fragment
first
amplifi
pcr
clone
directli
vector
takara
amplifi
pcr
clone
vector
gener
recombin
baculovirus
invitogen
carlsbad
ca
usa
clone
verifi
sequenc
cell
lysat
separ
polyacrylamid
gel
transfer
polyvinyliden
difluorid
membran
millipor
billerica
membran
block
subsequ
probe
murin
monoclon
antibodi
mab
respect
specif
influenza
ha
novu
biolog
commerci
ecl
kit
pierc
immunofluoresc
stain
perform
previous
describ
briefli
cell
infect
recombin
baculoviru
express
ha
protein
multipl
infect
moi
h
infect
cell
wash
fix
probe
primari
murin
mab
specif
influenza
ha
novu
biolog
follow
speciesspecif
secondari
antibodi
ptg
final
cell
stain
dapi
sigmaaldrich
counterstain
photograph
scan
confoc
microscopi
leica
flow
cytometri
perform
previous
describ
briefli
cell
infect
rbv
suspend
incub
primari
murin
mab
specif
influenza
ha
novu
biolog
min
ice
follow
speciesspecif
fitcconjug
secondari
antibodi
ptg
cell
wash
fix
paraformaldehyd
analyz
fac
calibur
instrument
becton
dickinson
san
jose
ca
hemagglutin
activ
assay
cellexpress
ha
protein
perform
previous
describ
briefli
infect
cell
express
wt
mutant
ultrason
prepar
ha
suspens
assay
ha
titer
ha
protein
assay
thermal
effect
ha
suspens
treat
indic
temperatur
c
min
erythrocyt
ad
rel
ratio
calcul
percentag
residu
ha
titer
incub
initi
ha
titer
batch
mean
rel
ratio
calcul
base
three
batch
inactiv
influenza
virus
use
assay
immun
sera
hemagglutin
inhibit
assay
perform
previous
describ
briefli
l
influenza
viru
four
ha
unit
use
hi
assay
hi
titer
defin
highest
dilut
serum
abl
inhibit
hemagglutin
cell
infect
recombin
wildtyp
baculovirus
describ
day
infect
cell
collect
ultrason
centrifug
g
min
c
supernat
centrifug
g
h
c
result
precipit
resuspend
pb
load
onto
step
sucros
gradient
ha
protein
enrich
centrifug
g
h
c
fraction
collect
gradient
interphas
ha
contenst
analyz
sixweekold
femal
balbc
mice
purchas
experiment
anim
center
sun
yatsen
univers
hous
microisol
unit
wt
tmha
oil
emuls
given
subcutan
inject
week
week
cell
lysat
infect
wildtyp
baculovirus
includ
neg
control
blood
sampl
collect
week
immun
challeng
vaccin
mice
first
anesthet
ether
challeng
intranas
lethal
dose
virus
l
inoculum
volum
week
final
boost
immun
mice
monitor
daili
day
challeng
surviv
weight
loss
experi
specif
lethal
dose
challeng
denot
haspecif
immunoglobulin
g
igg
igg
isotyp
antibodi
titer
mous
sera
analyz
enzymelink
immunosorb
assay
elisa
previous
describ
briefli
purifi
inactiv
viru
particl
concentr
gml
coat
incub
serial
dilut
serum
sampl
c
h
detect
hrpconjug
goat
antimous
igg
polyclon
antibodi
optic
densiti
read
nm
use
spectrophotomet
biotek
usa
endpoint
titer
determin
reciproc
final
dilut
give
threefold
optic
absorb
neg
control
number
splenocyt
secret
upon
antigen
stimul
determin
use
elispot
assay
ezsep
dakew
china
accord
manufactur
instruct
briefli
precoat
plate
seed
splenocyt
well
stimul
purifi
inactiv
influenza
virus
respect
concentr
gml
process
spot
count
use
immunospot
elispot
reader
biosi
germani
statist
analys
perform
use
student
twotail
test
equal
varianc
p
valu
p
less
consid
statist
signific
correspond
averag
crossreact
antiha
igg
titer
surviv
rate
analyz
linear
regress
use
spss
softwar
previou
studi
show
wildtyp
higher
thermal
stabil
mutant
mutat
two
cystein
present
transmembran
domain
tm
studi
first
compar
heteroprotect
infect
group
mice
n
subcutan
immun
twice
g
respect
cell
infect
wildtyp
recombin
baculoviru
wtrbv
includ
neg
control
nc
infect
intranas
mld
group
show
surviv
rate
respect
fig
c
contrast
group
show
surviv
rate
heteroprotect
fig
elisa
hemagglutinin
inhibit
hi
assay
reveal
group
elicit
appar
higher
signific
igg
antibodi
titer
hi
titer
antibodi
titer
group
data
shown
surviv
mice
show
weight
loss
recoveri
fig
fig
character
humor
cellular
immun
respons
ac
igg
isotyp
antibodi
titer
cognat
inactiv
virus
immun
sera
vaccin
mice
collect
measur
igg
isotyp
antibodi
titer
cognat
inactiv
virus
elisa
describ
section
df
crossreact
igg
titer
heterosubtyp
inactiv
virus
immun
sera
vaccin
mice
collect
measur
crossreact
igg
titer
heterosubtyp
inactiv
virus
elisa
describ
section
gi
number
splenocyt
splenocyt
mice
immun
protein
isol
week
final
immun
cell
determin
elispot
assay
cognat
heterosubtyp
inactiv
virus
use
stimul
result
express
number
spot
splenocyt
statist
signific
valu
hatm
hawt
indic
denot
p
denot
p
result
first
demonstr
capabl
heteroprotect
tm
critic
heteroprotect
sinc
two
tm
cystein
mutat
uniqu
present
ha
hypothes
less
heteroprotect
wildtyp
collect
hxwt
select
includ
tiv
vaccin
circul
chicken
potenti
caus
pandem
expect
mice
immun
infect
virus
heteroprotect
except
group
surviv
rate
fig
b
whether
heteroprotect
could
transfer
investig
replac
tmd
ha
tm
design
collect
hxtm
fig
express
hxtm
cell
affect
tm
replac
demonstr
western
blot
fig
immunofluoresc
stain
fig
flow
cytometri
fig
furthermor
hxtm
show
signific
increas
thermal
resist
correspond
hxwt
data
shown
effect
tm
replac
antibodi
cytokin
respons
analyz
hxwt
hxtm
express
cell
enrich
step
centrifug
immun
describ
section
sera
immun
mice
analyz
elisa
use
purifi
inactiv
virus
antigen
hemagglutinin
inhibit
assay
use
cognat
inactiv
virus
elispot
assay
use
purifi
inactiv
virus
stimul
hxtm
elicit
higher
signific
homolog
igg
titer
correspond
hxwt
data
shown
howev
hxtm
elicit
signific
higher
homolog
respons
correspond
hxwt
p
fig
addit
even
though
crossreact
igg
titer
low
hxtm
elicit
signific
higher
crossreact
igg
titer
correspond
hxwt
fig
regard
hi
titer
tm
replac
increas
appar
signific
homolog
hi
titer
data
shown
cytokin
product
hxtm
elicit
signific
higher
group
mice
immun
manner
describ
three
differ
dosag
ie
g
g
g
respect
two
week
boost
group
immun
infect
monitor
consecut
day
surviv
rate
group
immun
g
g
g
ha
protein
viru
b
rel
bodi
weight
graph
mice
immun
three
differ
dosag
g
g
g
infect
viru
product
correspond
hxwt
fig
product
data
shown
whether
increas
crossreact
antibodi
product
could
translat
heteroprotect
investig
group
mice
subcutan
immun
twice
g
hxwt
hxtm
respect
infect
intranas
mld
virus
group
show
surviv
rate
homolog
respect
fig
f
hxtm
show
higher
heteroprotect
correspond
hxwt
fig
group
group
surviv
rate
respect
group
surviv
rate
respect
homolog
infect
result
weight
loss
heterosubtyp
infect
caus
sever
weight
loss
data
shown
protein
show
less
bodi
weight
loss
higher
dosag
homolog
infect
ha
protein
whether
amount
protein
differenti
capabl
protect
homolog
infect
mice
investig
differ
group
mice
vaccin
g
ha
protein
infect
result
show
weight
loss
ha
vaccin
group
significantli
less
ha
vaccin
group
infect
surviv
rate
fig
test
dosag
effect
ha
protein
differ
group
mice
vaccin
g
g
g
ha
protein
increas
ha
protein
dosag
result
increas
serum
haspecif
igg
titer
homolog
viru
heterosubtyp
viru
data
shown
protect
heterosubtyp
infect
increas
along
increas
ha
protein
dosag
strikingli
protect
achiev
vaccin
g
ha
protein
mild
weight
loss
g
ha
protein
provid
protect
sever
weight
loss
fig
b
studi
demonstr
tm
critic
hainduc
heteroprotect
tmdepend
heteroprotect
could
transfer
replac
tm
tm
previou
studi
suggest
plausibl
correl
ha
stabil
heterosubtyp
immun
du
et
al
show
hemagglutinin
fragment
fuse
either
fc
human
igg
foldon
plu
fc
fusion
protein
express
cell
provid
crossclad
protect
weldon
et
al
show
solubl
ha
sha
deriv
viru
modifi
cterminu
trimer
repeat
stabil
nativ
trimer
structur
ha
fusion
protein
express
insect
cell
elicit
significantli
higher
igg
hai
titer
unmodifi
sha
recent
kanekiyo
et
al
show
ectodomain
ha
protein
fuse
ferritin
form
nanoparticl
eight
trimer
viral
spike
surfac
nanoparticl
vaccin
improv
potenc
breadth
influenza
viru
immun
addit
li
et
al
show
fulllength
ectodomain
spike
protein
sever
acut
respiratori
syndrom
sar
fuse
foldon
domain
deriv
bacteriophag
fusion
protein
induc
significantli
higher
titer
neutral
antibodi
result
higher
thermal
stabil
better
heteroprotect
provid
one
evid
support
plausibl
correl
result
demonstr
contain
replac
tm
show
increas
thermal
stabil
heteroprotect
indic
tmbase
heteroprotect
could
transfer
two
import
featur
one
recipi
restrict
one
particular
ha
subtyp
transfer
heteroprotect
restrict
one
heterosubtyp
infect
strongli
suggest
gener
applic
tm
replac
requisit
univers
vaccin
studi
undoubtedli
rais
mani
question
need
answer
exampl
imper
know
whether
effect
tm
replac
tmspecif
whether
tm
could
optim
elicit
even
higher
degre
heteroprotect
furthermor
increas
product
provid
one
explan
increas
titer
replac
hxtm
mutant
replac
tm
affect
product
clear
addit
immun
sera
show
detect
hi
titer
heterosubtyp
virus
data
shown
thu
would
interest
know
whether
crossreact
antibodi
provid
heteroprotect
antibodydepend
cellular
toxic
summari
result
demonstr
heteroprotect
ha
protein
could
enhanc
replac
tm
tm
strategi
replac
tm
ha
protein
would
conceiv
applic
ha
protein
especi
ha
protein
emerg
pandem
influenza
virus
studi
help
increas
heteroprotect
tiv
th
vaccin
develop
effect
vaccin
futur
influenza
pandem
viral
pathogen
declar
hve
finaci
person
relationship
peopl
organ
inappropri
influenc
work
profession
person
interest
natur
kind
product
servic
andor
compani
could
constru
influenc
posit
present
manuscript
